110 related articles for article (PubMed ID: 8534955)
1. Fixed drug eruption secondary to ondansetron.
Iglesias ME; España A; Redondo P; Quintanilla E
Dermatology; 1995; 191(3):270-1. PubMed ID: 8534955
[No Abstract] [Full Text] [Related]
2. Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2.
Bernand S; Scheidegger EP; Dummer R; Burg G
Dermatology; 2000; 201(2):148-50. PubMed ID: 11053919
[TBL] [Abstract][Full Text] [Related]
3. Anaphylactic reaction to ondansetron.
Weiss KS
Arch Intern Med; 2001 Oct; 161(18):2263. PubMed ID: 11575988
[No Abstract] [Full Text] [Related]
4. Isolated urticaria to ondansetron and successful treatment with granisetron.
Bousquet PJ; Co-Minh HB; Demoly P
Allergy; 2005 Apr; 60(4):543-4. PubMed ID: 15727597
[No Abstract] [Full Text] [Related]
5. Generalised seizures following ondansetron.
Sharma A; Raina V
Ann Oncol; 2001 Jan; 12(1):131-2. PubMed ID: 11249042
[No Abstract] [Full Text] [Related]
6. Ondansetron: reasons to be restrictive.
Frigerio C; Buchwalder PA; Spertini F
Lancet; 1996 May; 347(9013):1484-5. PubMed ID: 8676652
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs.
Bursztejn AC; Tréchot P; Cuny JF; Schmutz JL; Barbaud A
Contact Dermatitis; 2008 Jun; 58(6):365-8. PubMed ID: 18503688
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and toxicity of intra-arterial infusions of platidiam and nitrosomethylurea in disseminated melanoma of the skin of the extremities].
Shatikhin VA; Gorbunova VA; Dolgushin BI; Kuchinskiĭ GA
Sov Med; 1990; (2):116-8. PubMed ID: 2141436
[No Abstract] [Full Text] [Related]
10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
11. [Drug effectiveness or drug toxicity?].
Rosti L
Pediatr Med Chir; 2012; 34(5):244. PubMed ID: 23342751
[No Abstract] [Full Text] [Related]
12. Reticulated hyperpigmentation following chemotherapy for radiation-induced osteosarcoma.
Necessary CA; Roffwarg D; Ellis D
J Am Acad Dermatol; 2014 Jul; 71(1):e23-4. PubMed ID: 24947708
[No Abstract] [Full Text] [Related]
13. Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
Turner SR; Pinsk M
J Pediatr Hematol Oncol; 2008 Jan; 30(1):58-60. PubMed ID: 18176182
[TBL] [Abstract][Full Text] [Related]
14. Dermatological adverse reactions to cancer chemotherapy.
Pavey RA; Kambil SM; Bhat RM
Indian J Dermatol Venereol Leprol; 2015; 81(4):434. PubMed ID: 26144855
[No Abstract] [Full Text] [Related]
15. Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: A case report.
Akyurek FT; Sari N; Ugurluoglu C; Kurtipek GS
Dermatol Ther; 2019 Jul; 32(4):e12981. PubMed ID: 31168954
[TBL] [Abstract][Full Text] [Related]
16. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
17. [Fixed pigmented erythema caused by levamisole administration].
Clavère P; Bonnafoux-Clavère A; Delrous JL; Bonnetblanc JM; Olivier JP
Ann Dermatol Venereol; 1994; 121(3):238-9. PubMed ID: 7832552
[TBL] [Abstract][Full Text] [Related]
18. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron.
Pivot D; Javot L; Swiegot D; Petitpain N; Spaëth D; Trechot P
Therapie; 2013; 68(6):409-10. PubMed ID: 24246123
[No Abstract] [Full Text] [Related]
19. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
[TBL] [Abstract][Full Text] [Related]
20. Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.
Lim JL; Dahiya M; Burgin S
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S60-1. PubMed ID: 18625394
[No Abstract] [Full Text] [Related]
[Next] [New Search]
